MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PIRAMAL ENTERPRISES LTD. (pharmaceuticals)
- Latest 8 Quarter Result
Piramal Healthcare Quarterly Results 
(NCHP)
Here are the latest quarterly results of Piramal Healthcare. For more details, see the Piramal Healthcare financial fact sheet and Piramal Healthcare share price and chart. For a sector overview, read our pharmaceuticals sector report.
Piramal Healthcare Quarterly Results
| No. of Mths Qtr. Ending |
3
Jun-17* |
3
Sep-17* |
3
Dec-17* |
3
Mar-18* |
3
Jun-18* |
3
Sep-18* |
3
Dec-18* |
3
Mar-19* |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 22,541 | 25,359 | 28,584 | 29,911 | 29,025 | 31,441 | 34,891 | 36,797 | |
| Other income | Rs m | 838 | 754 | 638 | 365 | 144 | 563 | 1,028 | 852 | |
| Turnover | Rs m | 23,379 | 26,113 | 29,222 | 30,276 | 29,169 | 32,004 | 35,919 | 37,649 | |
| Expenses | Rs m | 11,923 | 12,660 | 14,110 | 16,103 | 13,758 | 14,911 | 14,618 | 17,380 | |
| Gross profit | Rs m | 10,618 | 12,699 | 14,474 | 14,732 | 10,744 | 17,264 | 20,273 | 19,283 | |
| Depreciation | Rs m | 1,229 | 1,293 | 1,100 | 1,151 | 1,288 | 1,234 | 1,326 | 1,354 | |
| Interest | Rs m | 6,732 | 7,247 | 7,497 | 8,306 | 9,091 | 10,162 | 11,688 | 13,157 | |
| Profit before tax | Rs m | 3,495 | 4,912 | 6,515 | 5,640 | 510 | 6,432 | 8,287 | 5,624 | |
| Tax | Rs m | 1,021 | 1,898 | 2,118 | -33,800 | 1,810 | 1,628 | 2,930 | 2,243 | |
| Profit after tax | Rs m | 2,475 | 3,015 | 4,397 | 39,440 | -1,300 | 4,804 | 5,356 | 3,381 | |
| Gross profit margin | % | 47.1 | 50.1 | 50.6 | 49.3 | 37.0 | 54.9 | 58.1 | 52.4 | |
| Effective tax rate | % | 29.2 | 38.6 | 32.5 | -599.3 | 355.1 | 25.3 | 35.4 | 39.9 | |
| Net profit margin | % | 11.0 | 11.9 | 15.4 | 131.9 | -4.5 | 15.3 | 15.4 | 9.2 | |
| Diluted EPS | Rs | 14.3 | 17.5 | 25.5 | 228.6 | -7.5 | 27.8 | 31.0 | 19.6 | |
| Diluted EPS (TTM) | Rs | 72.7 | 72.4 | 74.5 | 285.8 | 264.0 | 274.3 | 279.9 | 70.9 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Piramal Healthcare 4QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: INDOCO REMEDIES FRESENIUS KABI ONCO. AUROBINDO PHARMA MERCK FULFORD INDIA
Compare PIRAMAL ENTERPRISES With: INDOCO REMEDIES FRESENIUS KABI ONCO. AUROBINDO PHARMA MERCK FULFORD INDIA
Compare PIRAMAL ENTERPRISES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 140 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets ended their day on a positive note today ahead of counting of Lok Sabha Election 2019 to be done tomorrow.
Views on news
PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)
Apr 30, 2019 | Updated on Apr 30, 2019For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)
Jan 30, 2019 | Updated on Jan 30, 2019For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)
May 10, 2019The one critical element that has made Amazon a force to reckon with...
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)
May 9, 2019A filtered, neat list of high-dividend stocks with all this dirty work already done for you.
The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)
May 14, 2019These companies will help the Sensex more than double from current levels.
More|
| |
PIRAMAL ENTERPRISES SHARE PRICE
May 22, 2019 (Close)
TRACK PIRAMAL ENTERPRISES
- Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PIRAMAL ENTERPRISES
PIRAMAL ENTERPRISES 5-YR ANALYSIS
COMPARE PIRAMAL ENTERPRISES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.